Background: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody administered with a 20 mg subcutaneous monthly dosing regimen. Methods: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald criteria; 2) who started OFA according to Italian Medicines Agency prescription rules and within 12 months from the RMS diagnosis; 3) naïve to any disease-modifying therapy. The primary outcome was to offer an overview of cellular subsets of RMS naïve patients (time 0) and then after 4 weeks (time 1) and 12 weeks (time 2) on therapy with OFA in a real-world setting. Results: Fifteen patients were enrolled. CD3+ T cell frequencies were higher at time 1 ( .4, SD 7.7) and time 2 ( .6, SD 5.8) when compared to time 0 (r.4, SD 9.8), p = .013. B naïve cells were barely detectable in the OFA group at time 1 (%0.4, SD 0.5) and 2 (%1.4, SD 2.9) when compared to time 0 ( .5, SD 3.8), p < .001. Conclusion: The progressive and increasing use of anti-CD20 drugs imposes the need for larger, prospective, real-world, long-term studies to characterize further immunophenotypes of patients with RMS treated with OFA.

D'Amico, E., Zanghì, A., Fantozzi, R., Centonze, D., Avolio, C. (2023). Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study. CURRENT NEUROPHARMACOLOGY, 21(12), 2563-2566 [10.2174/1570159X21666230803161825].

Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study

Centonze, Diego;
2023-01-01

Abstract

Background: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody administered with a 20 mg subcutaneous monthly dosing regimen. Methods: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald criteria; 2) who started OFA according to Italian Medicines Agency prescription rules and within 12 months from the RMS diagnosis; 3) naïve to any disease-modifying therapy. The primary outcome was to offer an overview of cellular subsets of RMS naïve patients (time 0) and then after 4 weeks (time 1) and 12 weeks (time 2) on therapy with OFA in a real-world setting. Results: Fifteen patients were enrolled. CD3+ T cell frequencies were higher at time 1 ( .4, SD 7.7) and time 2 ( .6, SD 5.8) when compared to time 0 (r.4, SD 9.8), p = .013. B naïve cells were barely detectable in the OFA group at time 1 (%0.4, SD 0.5) and 2 (%1.4, SD 2.9) when compared to time 0 ( .5, SD 3.8), p < .001. Conclusion: The progressive and increasing use of anti-CD20 drugs imposes the need for larger, prospective, real-world, long-term studies to characterize further immunophenotypes of patients with RMS treated with OFA.
2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26
English
Ofatumumab
anti-CD20
b-cells
immunological cells subset
immunophenotype
multiple sclerosis
D'Amico, E., Zanghì, A., Fantozzi, R., Centonze, D., Avolio, C. (2023). Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study. CURRENT NEUROPHARMACOLOGY, 21(12), 2563-2566 [10.2174/1570159X21666230803161825].
D'Amico, E; Zanghì, A; Fantozzi, R; Centonze, D; Avolio, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
CN-21-12-15.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 4.14 MB
Formato Adobe PDF
4.14 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/341666
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact